## JACOBSON, PRICE, HOLMAN & STERN 400 SEVENTH STREET, N.W.

WASHINGTON, D.C. 20004-2201

## LIST OF P

ATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

ATTY. D SERIAL APPLICA	NO.:		11,700	GROUP ART FILING DAT HLINGENSIEPEN et	E: <u>Jul</u>	o Be As y 27, 1	
*****	****	*****		**************************************	*****	*****	*****
*EXAMINER		DOCUMENT				SUB-	CTITUE DAME
INITIAL		NUMBER	DATE	NAME	CLASS	CLASS	FILING DATE
INTITAL		NOMER	DATE	NAME	CHASS	CTHOS	(If Appropriate)
	AA						
	AB						
-	AD		-				
++++++		*****				والمراك والمراك والمراك والمراك	*****
					****	*****	*****
			FUREIGN E	PATENT DOCUMENTS			
		DOCUMENT				SUB-	TRANSLATION
_		NUMBER	DATE	COUNTRY	<u>CLASS</u>	<u>CLASS</u>	(YES) (NO)
$\bigcirc$							
	AC	WO94/25588	11/10/94	WO			<u> </u>
$\mathcal{L}$	AD	WO93/07883	04/29/93	WO			:
	ΑE	W096/39415	12/12/96	WO			•
	AF	WO95/00103	01/05/95	WO			•
	AG	W095/02422	01/26/95	WO			
<del></del>	AH	WO96/31600	10/10/96	WO			
	AI	$\frac{WO90/31800}{WO90/10030}$	09/07/90				<del></del>
	AI	WO90/10030	09/07/90	WO			<u>:</u>
	THER	ART (Includi	ing Author,	**************************************	tinent Pa	ages, E	tc.)
1	AJ	Yu et al.,	'Hybrid Olic	onucleotides: S	ynthesis,	Bioph	ysical
		Properties,	Stability S	Studies, and Biol	ogical A	ctivity	7,"
u U		Bioorganic 8	Medicinal	Chemistry, 4(10)	:1685-169	$\frac{1}{2}$ (199	6)
1	AK						
	7110	Zhao et al., "Effect of Different Chemically Modified Oligodeoxynucleotides on Immune Stimulation," Biochemical					
					CTOIL D.	LOCITEILL	Cal
1		Pharmacology," 51(2):173-182 (1996)					
	$\mathtt{AL}$	Hatzfeld, "Release of Early Human Hematopoietic Progenitors					
l l		from Ouiesc	ence by Ant:	isense Transformi	ng Growt	h Facto	or β1 or
		or Rb Oligo	nucleotides	" Journal of Exp	erimenta:	l Medic	ine.
		174(4):925-	929 (1991)	-			
	AM	Fitzpatrick		ntisense Oligonu	clentides	Sneci	fic for
				tor β2 Inhibit t			
		Mesotheliom		itro and in Vivo.			
				icio and in vivo.	Cancer	Reseal	CII
	\	<u>57:3200-320</u>	7 (1997)				
	<del>\</del>				-,		
EXAMINER\		e 2		DATE CONSIDERED	8/18/6	<b>)</b> O	
$\overline{}$	1	<del>-</del> -			21,0/		<del> </del>
+ = = = = =	1,	16		L -: L-: -: -:		0 0 11	
* EXAMINER:	formance	and not considered.	ered, whether or no Include copy of t	t citation is in conformanchis form with next communic	e with MPEP 60 ation to appli	y; Draw lin cant(s).	e through citation

## JACOBSON, PRICE, HOLMAN & STERN

400 SEVENTH STREET, N.W. WASHINGTON, D.C. 20004-2201

LIST OF P
ATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

ATTY. SERIAL APPLIC	NO.:	09/341,700 FILING DATE: July 27, 1999							
********************									
	OTHER	ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
13	AN	Pisetsky et al., "Stimulation of in vitro proliferation of							
110	,	murine lymphocytes by synthetic oligonucleotides," Molecular							
	AO	Biology Reports, 18(3):217-221 (1993)  Jachimczak et al., "Transforming growth factor β-mediated							
	HO	autocrine growth regulation of gliomas as detected with							
1		phosphorothicate antisense oligonucleotides," International							
		Journal of Cancer, 65(3):332-337 (1996)							
	AP	Jachimczak et al., "The effect of transforming growth factor							
j		$\beta_2$ -specific phosphorothioate-anti-sense oligonucleotides in							
1/		reversing cellular immunosuppression in malignant glioma,"							
	AQ	78:944-951 (1993) Agrawal, "Antisense oligonucleotides: towards clinical							
	ΑQ	trials." Trends in Biotechnology, 14(10):376-387 (1996)							
<u> </u>									
EXAMINER		DATE CONSIDERED 8/18/00							
* EXAMINER	R: Initia conformanc	l if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation a and not considered. Include copy of this form with next communication to applicant(s).							

